CareDx Starts Enrollment in MAPLE, a Multi-modal, Multi-center, Prospective Study of LiverCare
Study to demonstrate utility of LiverCare post-transplant surveillance for liver transplant recipientsSOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the enrollment of the first patient in the Molecular Assessment and Profiling of Liver Transplant Recipients (MAPLE) Study at Mount Sinai Hospital in New York. MAPLE is a multi-center, prosp...